Delivery Order SPE2DB22D2006-SPE2DB25FW2MN
- Not listed
- The Defense Logistics Agency awarded a $1,679.83 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Exforge 5-320 mg tablets (30-count). This firm fixed-price contract, with an ultimate completion date of July 29, 2025, represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate headquarters in...
- The Defense Logistics Agency awarded a $1,007.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Exforge 5-320 mg on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, which is also the headquarters location of...
- The Defense Logistics Agency awarded a delivery order valued at $2,744.54 to AmerisourceBergen Drug Corp for the supply of Exforge HCT 10-160-12.5 mg tablets (30-count bottles) on September 3, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside designation and represents a single pharmaceutical supply transaction under the company's existing contract vehicle. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Exforge 10-320 mg tablets (30-count) under a firm fixed-price contract with a ceiling value of $3,399.87. This non-set-aside award, issued on June 25, 2025, with an ultimate completion date of June 26, 2025, represents a single delivery order for this antihypertensive medication to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Exforge 10-320 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $1,078.23. The award was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the same location designated as...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division for the procurement of Exforge 10-160 mg tablets. The order, valued at $4,515.18, is a firm fixed-price contract with a completion date of May 23, 2024. AmerisourceBergen, a major pharmaceutical distribution company, holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 17, 2025, for Exforge 5-320 mg tablets (30-count units) valued at $2,867.33. This competitive award, issued without set-aside designation, represents a firm fixed-price contract with an ultimate completion date of July 18, 2025. The place of performance is located at AmerisourceBergen's Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a delivery order valued at $1,826.35 to AmerisourceBergen Drug Corp for EXFORGE 5-160 MG tablets (30-count supply) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through December 2026. The...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,258.65 firm fixed-price delivery order (SPE2DB20D3101|SPE2DB23FQUV5) is for 30-count packages of the medication Exforge HCT 10-320-25 mg tablets. The contract has an ultimate completion date of November 16, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,001.00 firm fixed-price delivery order is for the supply of EXFORGE 10-160 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of June 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2MNDelivery Order
The Defense Logistics Agency awarded a $3,768.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Exforge 10-320 mg on July 14, 2025, with completion expected by July 15, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, medical devices, and specialized healthcare commodities to military healthcare programs and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive federal contract portfolio demonstrating its capability to meet competitive procurement requirements across diverse therapeutic domains and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 7/14/25 |